The government sets retail prices for 23 drug formulations 2023


On Friday, the National Pharmaceutical Pricing Authority (NPPA) announced that it had established retail prices for 23 different formulations. These prices include those for drugs used to treat diabetes and high blood pressure.

On the basis of the decision made at the 113th Authority meeting on May 26, 2023, the National Pharmaceutical Pricing Authority (NPPA) has established the prices that are to be followed in accordance with the Drugs (Price Control) Order, 2013.

According to the announcement, the National Pharmaceutical Pricing Authority (NPPA) has decided that the cost of one pill of the diabetic medication Gliclazide ER and Metformin Hydrochloride tablets will be Rs 10,03.

These 23 drugs treat diabetes and hypertension.

In a similar vein, one pill of telmisartan, chlorthalidone, and cilnidipine tablets may be purchased in stores for the equivalent of Rs 13.17. The price of one tablet of the pain reliever drug containing Trypsin, Bromelain, Rutoside Trihydrate and Diclofenac Sodium has been set at Rs 20.51 on the retail market.

The National Pharmaceutical Pricing Authority (NPPA) stated that it has also increased the ceiling price of 15 scheduled formulations in accordance with the Drugs (Prices Control) Order, 2013 (NLEM 2022).

In addition to that, it has a price cap that is established for two different planned formulations.

In addition to that, the notification said that it has a set and amended ceiling price for one of the scheduled formulations.

The NPPA has been given the responsibility of establishing and revising the pricing of restricted bulk pharmaceuticals and formulations, as well as enforcing prices and ensuring availability of medicines across the nation. In addition to this, it monitors the pricing of pharmaceuticals that are no longer restricted in order to ensure that they remain at acceptable levels.

The regulator is responsible for putting the provisions of the Drugs (Prices Control) Order into action and enforcing them. It is also charged with the responsibility of recouping from customers any monies that medication producers have improperly overcharged for prohibited substances.

Leave a Reply